Inflazome develops orally available small‑molecule drugs that target the NLRP3 inflammasome to address unmet needs in inflammatory and neurodegenerative diseases. The company is pursuing both therapeutic programs and diagnostic tools to improve patient selection and demonstrate central nervous system target engagement. Inflazome cites preclinical research showing the tool compound MCC950, an NLRP3 inhibitor, arrested neuroinflammation and reduced neuron loss in multiple animal models. To support clinical translation, Inflazome is developing an NLRP3‑specific PET tracer to non‑invasively image inflammasome activity in the brain and guide dosing in future trials. The company has received grant funding to advance this tracer work and says the tracer could help select suitable patients at the right disease stage. Leadership on the PET project includes Prof. Matthew Cooper (CEO and co‑founder) as Principal Investigator and Dr. David Miller (Head of Medicinal Chemistry) as Co‑Investigator. Inflazome is developing potent, selective small-molecule inhibitors of the NLRP3 inflammasome to stop the cycle of chronic inflammation. Its pipeline targets a broad range of diseases driven by NLRP3 overactivity, including Alzheimer’s, Parkinson’s, inflammatory bowel disease, gout, osteoarthritis, and liver, kidney and cardiovascular diseases. The company plans to advance its first-in-class NLRP3 inhibitors into multiple clinical trials in 2019, with next-generation compounds to follow. Inflazome completed a €40 million ($46 million) Series B to fund these clinical development plans. The company was founded in 2016 and is headquartered in Dublin, Ireland; it was co-founded by Prof. Matt Cooper and Prof. Luke O’Neill. Following the financing, Forbion and Longitude Capital representatives joined Inflazome’s board. Inflazome is developing orally available small‑molecule inhibitors that target the inflammasome, a regulator of innate immunity implicated in many chronic inflammatory diseases. The company aims to stop the cycle of chronic inflammation in conditions ranging from Parkinson’s to asthma, where current therapies are often inadequate. Inflazome was founded by Prof. Matt Cooper and Prof. Luke O’Neill and has assembled industry and academic leadership including VP of Business Development Dr. Jeremy Skillington. The company closed a Series A financing of up to US$17/€15 million to advance its programs. Founding investors and Series A co‑leaders are Fountain Healthcare Partners and Novartis Venture Fund. Management emphasizes broad commercial potential for a successful small‑molecule inflammasome inhibitor across multiple inflammatory indications.

Total raised

$64M

Funding rounds

3

Latest round

Grant

Latest activity

Mar 2019